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Abstract
Crohn's disease (CD) presents as an inflammatory barrier disease with characteristic destructive
processes in the intestinal wall. Although the pathomechanisms of CD are still not exactly
understood, there is evidence that, in addition to e.g. bacterial colonisation, genetic predisposition
contributes to the development of CD. In order to search for predisposing genetic factors we
scrutinised 245 microsatellite markers in a population-based linkage mapping study. These
microsatellites cover gene loci the encoded protein of which take part in the regulation of
apoptosis and (innate) immune processes. Respective loci contribute to the activation/suppression
of apoptosis, are involved in signal transduction and cell cycle regulators or they belong to the
tumor necrosis factor superfamily, caspase related genes or the BCL2 family. Furthermore, several
cytokines as well as chemokines were included. The approach is based on three steps: analyzing
pooled DNAs of patients and controls, verification of significantly differing microsatellite markers
by genotyping individual DNA samples and, finally, additional reinvestigation of the respective gene
in the region covered by the associated microsatellite by analysing single-nucleotide polymorphisms
(SNPs). Using this step-wise process we were unable to demonstrate evidence for genetic
predisposition of the chosen apoptosis- and immunity-related genes with respect to susceptibility
for CD.
Introduction
Crohn's disease (CD) is a chronic inflammatory disorder
characterized by destructive processes in the intestinal
wall. Interactions between genetic and environmental fac-
tors potentially lead to an imbalance between the luminal
bacterial flora, and the innate as well as the adaptive
immune systems [1,2]. Epidemiological and genome
wide studies have lead to the identification of factors
establishing genetic involvement in CD [1,3,4]. Despite of
fundamental findings, namely the variation in the
CARD15 receptor and their association with CD, the caus-
ative instances regulating the exaggerated mucosal
response remained elusive. The proposed pathomecha-
nisms of CD are manifold. The dysregulated response of
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Table 1: Genes investigated for CD association as represented by an intra- or juxtagenic microsatellite marker (for additional 
information see URL: http://www.ruhr-uni-bochum.de/mhg/marker_information_SENW.pdf)
apoptosis related REQ TNFSF12 CTLA4 Casp10 IL4
RNF7 TNFSF14 DAP Casp14 IL4R
SMAC TNFSF15 DAPK1 Casp2 IL6
AIF TIAF1 TNFSF18 FADD Casp3 IL8
APR3 TIAL1 TNFSF4 IKBKG Casp4 IRF1
BCLG TP73 TNFSF5 MADD Casp5 NRG1B
BFAR VDR TNFSF6 MAP2K6 Casp6 PRL
CIDEB TNFSF7 MAP3K14 Casp7 PRLR
CYBB Bcl2 related TNFSF8 MAP3K5 Casp8
CYP51 TNFSF9 MAP4K4 CASP8AP2 chromosome 6
DAD1 BCL2A1 TOSO NFKB1 Casp9
DAP3 Bag1 NFKB2 No.1
DATF1 BAK innate immunity NSMAF apoptosis suppressor No.4
DAXX BAX PAWR No.5
DEDD BCL2 BPI PIAS3 No.6
DHCR24 BCL2L1 CD14 PTEN API5 No.7
EIF4G2 BCL2L11 CD5L RARB BIRC1 No.8
FASTK BCL2L13 DEFB119/ DEFB121 RIPK1 BIRC2 D6S1014
FLIP BID DEFB127 RIPK2 BIRC3 D6S1959
FRZB BIK HBD1 RIPK3 BIRC4 D6S273
GSK3B BNIP3L IFNB1 RXRB BIRC6
GSR MCL1 LY64 STK17A BIRC8 others
GZMA LY86 STK17B
GZMB TNF superfamily LY96 TANK cytokine chemokines BPHL/TUBB
HLCS NCF1 TRADD TAPBPR
NME3 LTB (TNFSF3) NCF4 Traf3 VEGF
NOL3 LTBR (TNFRSF3) PGLYRP Traf4 AXL LGALS3
NOS1 TNFa PLA2G4A Traf5 CSF1R BDNF
NOS2A TNFRSF10A PLUNC Traf6 CSF2 NGFB
NOX1 TNFRSF10B SerpinA1 CSF2RB NGFR
NOX3 TNFRSF10C SerpinB1 cell cycle regulators CSF3 TrkC
NOX4 TNFRSF10D SFTPA1 Dtk
P2RX1 TNFRSF11A SLPI CCND2 erbB3 positive control
P53AIP1 TNFRSF11B STAT3 CDC2 GAS1 CARD15
PDCD10 TNFRSF12 TGFB1 CDKN1A IGF1
PDCD2 TNFRSF17 TLR1 CDKN2A IGF2R
PDCD5 TNFRSF18 TLR2 PAK1B IL10
PDCD6 TNFRSF19 TLR3 RbAp48 IL10RA
PDCD6IP TNFRSF19L TLR4 Rb2/p130 IL10RB
PDCD8 TNFRSF1A TLR5 RBP1 IL11RA
PLA2G10 TNFRSF1B TLR7 RBP2 IL12A
PLA2G1B TNFRSF21 TLR8 RBQ-1 IL12B
PLA2G6 TNFRSF4 TLR9 RBQ-3 IL12RB2
PTGS1 TNFRSF5 TLR10 TP53 IL13RA2
REQ TNFRSF6 (FAS) TP53INP1 IL18
RNF7 TNFRSF6B signal transduction IL18R
SMAC TNFRSF7 caspase related IL1RL1
TIAF1 TNFRSF8 Traf1 IL1B
TIAL1 TNFRSF9 BCL10 ADPRT IL2
TP73 TNFSF10 CHUK CARD4 IL24
VDR TNFSF11 CRADD Casp1 IL2RAJournal of Negative Results in BioMedicine 2005, 4:8 http://www.jnrbm.com/content/4/1/8
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the innate immune system is supposed to present a crucial
step in the pathogenesis of CD [5]. This fact has been con-
firmed genetically by several CD associations of genes
such as CD14, TLR4 and in some instances the interaction
of their variations with CARD15 [6,7]. In regard to the
polarized T helper (Th) response, the adaptive immune
system appears affected in CD as well [8-10]. Moreover,
several studies implicated a role of programmed cell death
in CD [11-15]. Apoptosis mediates 'self-tolerance', the
elimination of autoreactive immune compartments. In
addition, the thoroughly controlled termination of a
physiological immune response is due to the process of
programmed cell death. In CD mucosal T cells show less
susceptibility to apoptosis [16]. In this context TNFα pro-
tein exerts multiple physiological effects, and anti-TNFα
therapeutic strategies (e.g. infliximab) are effective in
(maintaining) remission of CD [17]. In several studies it
has been revealed that treatment of CD patients with inf-
liximab leads to an activation of T cells rendering them
susceptible for apoptosis [18,19]. Interestingly, the effect
of this treatment may not be due to neutralisation of sol-
uble TNFα (and its binding to the TNFRs), but rather it
may be caused by its affinity to membrane-bound TNFα
putatively changing the ratio of anti- and pro-apoptotic
mediators towards induction of apoptosis [18,20].
Although the mechanisms of the causal role of T cells
responses in CD remain to be determined in detail, there
is substantial clinical evidence that suggests a role for
uncontrolled activated T lymphocytes in the pathogenic
process of CD [21-24]. Nevertheless, it is uncertain,
whether a genetic basis for a decreased activation/apopto-
sis of T lymphocytes in CD patients exists, and whether
increased anti-apoptotic markers, found in T cells of these
patients are due to the mucosal inflammation, secondar-
ily [18].
In such a complex situation we used extended association
screening (EAS) with markers representing 245 apoptosis-
and (innate) immunity-related genes. The majority of the
investigated markers have been successfully utilized in
respective studies before [25,26]. Our population based
linkage mapping comprises a 3-stage analysis with pooled
DNA in the initial phase and subsequently individual gen-
otyping. In order to confirm such results, several tagging
SNPs of the adjacent gene represented by the marker were
analysed. Here, we investigated the role of distinct biolog-
ical pathways for the susceptibility of CD.
Materials and methods
Patients
One hundred and fifty eight well-characterized patients
with a clinical, endoscopical and histological diagnosis of
CD were included. This patient cohort has been reported
before [27,28]. All patients were of German origin and the
diagnosis of CD was adjusted according to the diagnostic
criteria of the European Community Workshop on
Inflammatory Bowel Diseases (IBD). As controls a group
of healthy northern German (NoG) and western German
(WeG) origin were analysed. In the initial step a group of
~100 NoG individuals were used. In order to exclude pop-
ulation stratification, genotyping of chosen SNPs was per-
formed in 180–460 NoG and WeG individuals.
Pooling of DNA
The DNA concentration from each individual of the
patient and control cohorts was quantified by spectropho-
tometry, carried out four times, and then diluted accord-
ingly to 100 ng/µl. In a second step the DNA was diluted
to a concentration of 65 ng/µl and once more measured
by spectrophotometry. Finally, DNA diluted to 50 ng/µl
was adjusted to a final amount of 1000 ng for each indi-
vidual in a pool of 50 persons. In the initial stage, marker
analyses were performed with two patient and two control
subpools, respectively.
Tailed primer PCR
Tailed primer PCR was performed as described before
[25]: An 18 bp-tail was added to each sense oligonucle-
otide. PCR reaction included three oligonulceotides, two
of which were target specific. The third one consists of the
same sequence as the abovementioned tail that was addi-
tionally fluorescence-labelled.
Microsatellite markers
Intragenic microsatellite or markers located in the imme-
diate vicinity (<50 kb) of the specific gene were included.
Information on the oligonucleotide sequences and loca-
tion of markers are given at the website (Additional file 1;
see also Tab. 1). As reported before, only markers with
equal "intra-subgroup" allele distributions with ≥ 2 alleles
were considered in subsequent analyses [25]. Significantly
associated markers were genotyped individually in order
to exclude false-positive results due to possible pooling
artefacts. All in all, 245 microsatellite markers represent-
ing distinct genes were analysed on an ABI377 slab-gel
system (Applied Biosystems, Darmstadt, Germany).
Statistics for initial comparisons of allele frequencies
Raw data from ABI377 profiles were analysed by the Gen-
otyper software (ABI) producing a marker specific allele
image profile (AIP) which includes different heights of
peaks reflecting the allele frequencies. In order to test dif-
ferences of the AIPs between CD patients and the controls,
all peak heights were summarized for each pool and set to
100 %. The total allele count for each distinct allele was
then estimated. Thereupon, the AIPs of the case and con-
trol pools were compared statistically by means of contin-
gency tables. Hence, P values are nominal and
approximate, because estimated rather than observed
counts were used for allele frequencies. The significanceJournal of Negative Results in BioMedicine 2005, 4:8 http://www.jnrbm.com/content/4/1/8
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level was set at p = 0.05. In order to focus the statistics on
major alleles, all minor alleles with a frequency of less
than 0.05 were summarized to a virtual allele. Subse-
quently, a second statistical analysis by means of contin-
gency tables was undertaken. A third step for statistical
testing each allele individually was accomplished (and the
summation of all other marker alleles), whereby the
respective value of the patient group was compared with
those of the controls and subsequent χ2 analyses. Despite
of evidence that correction for multiple comparisons
might eliminate 'real positive' results [26], Q value correc-
tion was performed with a cut off of 5% for the initial
screening procedure [29].
Nevertheless, for selecting markers for further investiga-
tions, non-corrected P values were simply ranked accord-
ing to their evidence for association including all
performed statistical procedures.
Individual genotyping
Markers with significantly different allele distributions
between patients and controls were controlled by geno-
typing individual DNA samples of patients and controls
in order to exclude false-positive results due to pooling
artefacts. Individual genotyping was performed by capil-
lary gel electrophoresis by using the BeckmanCoulter
CEQ8000 genetic analysis system (Beckman Coulter, Ger-
many). Results were analysed by comparing each micros-
atellite allele frequency from the CD cohort with the
corresponding allele frequency of the control group by χ2
testing and corrected by the number of marker specific
alleles according to Bonferroni (see Tab. 2 and URL: http:/
/www.ruhr-uni-bochum.de/mhg/
marker_information_SENW.pdf). Hardy-Weinberg equi-
librium (HWE) was tested using the Genepop program
http://wbiomed.curtin.edu.au/genepop.
SNP genotyping
SNPs in genes as represented by significantly associated
markers after individual genotyping were investigated by
analysis of restriction fragment length polymorphisms
(RFLP; see Tab. 3). As the marker representing the
TNFRSF17 gene is located in ~1 MBp distance to the MHC
class II transactivator (MHC2TA) gene, a functional varia-
tion (rs3087456, [30]) of MHC2TA  was genotyped by
RFLP analyses in 147 CD patients and 463 healthy con-
trols from the abovementioned control populations (see
Tab. 3). The results were evaluated by means of χ2 -and
HWE testing. Linkage disequilibrium (LD) between the
marker alleles and the polymorphism was calculated by
the Genepop program.
Results
Initial step
Microsatellites representing 245 genes involved in apop-
tosis regulation (see Tab. 1) were investigated by using
EAS. None of the markers presented with significant intra-
subgroup differences confirming the homogeneity of the
pools. The statistical evaluation of the microsatellite fre-
quencies in the CD patient and the control cohorts
revealed 9 significantly different allele distributions of
intra- or juxtagenic markers for FLIP, BCL2A1, BAG1, BPI,
Table 2: P values for microsatellite markers located intragenically or in the immediate vicinity of represented genes after the initial 
step and individual genotyping.
p values
gene (as 
represented by the 
respective marker)
after analysis 
with pooled DNA
after summation of 
alleles beneath 5%
after analyses of 
each single allele 
(most significant 
allele)
after individual 
genotyping1 (pc 
value)
after correction by 
Q-value of pooled 
data
FLIP 0.2871 0.1936 0.0100 0.0044 (pc > 0.05; c = 9) n.s.
BCL2A1 0.0948 0.0948 0.0275 n.s. n.s.
BAG1 0.2541 0.2541 0.0163 n.s. n.s.
BPI 0.0011 0.0011 0.0031 n.s. n.s.
erbB3 0.0760 0.0932 0.0100 n.s. n.s.
TP73 0.5928 0.3535 0.0302 n.s. n.s.
TLR9 0.3004 0.3004 0.0300 n.s. n.s.
TNFRSF17 0.0012 0.0014 0.0014 0.0012 (pc < 0.01; c = 6) n.s.
CARD15 0.0083 0.0247 0.0054 0.0050 (pc < 0.04; c = 7) n.s.
P values were generated using three different procedures as described in the methods' section. Briefly, data were analysed by means of contingency 
tables, initially comparing allele distributions represented by the AIF (after analyses with pooled DNA), then after summation of alleles < 5% in 
order to focus on the major alleles and, finally, after comparison of each single allele between the control and patient cohorts. For analysing the 
results of the individual genotyping χ2 testing was utilised.
1Genotyping was performed with the same individuals used in the pooling procedure, and, when remaining significant, further individuals were 
added to the analyses (FLIP: CD = 134, controls = 150; TNFRSF17: CD = 147, controls = 135; CARD15: CD = 144, controls = 165).Journal of Negative Results in BioMedicine 2005, 4:8 http://www.jnrbm.com/content/4/1/8
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erbB3, TP73, TLR9, TNFRSF17 and CARD15 (summarized
in Tab. 2).
Individual genotyping
Individual genotyping confirmed significant P values only
for the 3 markers FLIP (p = 0.0044, pc > 0.05, in HWE),
TNFRSF17 (p = 0.0012, pc < 0.01, in HWE) and the posi-
tive control CARD15 (p = 0.0050, pc < 0.04, in HWE). The
additional associations for the other markers were rejected
(see Tab. 2 and Additional file 1). There were no differ-
ences analysing CARD15+ and CARD15- patients.
SNP genotyping
SNP markers (Tab. 3) were genotyped located in the
respective genes in the vicinity of the microsatellites repre-
senting TNFRSF17 and FLIP. Thus, SNPs were analyzed
spread across the genes representing haplotypes as predis-
posed by the 'LD Select' method reported before [31].
RFLP analyses did not reveal any association of the
selected SNPs, neither by comparing the CARD15+ nor the
CARD15- patients with the control group.
Comparison of TNFRSF17 microsatellite alleles
The genotypes of the TNFRSF17 microsatellite alleles were
compared between the patient and control cohorts. Anal-
yses revealed evidence either for a predisposing (allele 3)
and a protective allele (2) or linkage between these alleles
and the marker alleles, respectively.
Genotypes including allele 2 are overrepresented in the
control cohort, whereas those with the apparently predis-
posing allele 3 are more frequent in the CD cohort, thus
confirming the results of individual genotyping (see Fig.
1).
MHC2TA analyses
The analyses of the functionally significant polymor-
phism rs3087456 revealed a marginal association in our
CD patients when allele or genotype frequencies were
compared between the combined control (WeG and NoG
did not differ in allele frequencies) and the patient
cohorts (see Tab. 4). Analyses for LD between TNFRSF17
and MHC2TA alleles, however, did not reveal any signifi-
cant deviations from equilibrium.
Discussion
The pathomechanisms of CD are still not exactly under-
stood, albeit certain CARD15 variations appear especially
frequent in CD patients; thus genetic involvement is
proven. These genetic predisposition factors, however, are
neither sufficient nor explain they the pathogenesis in all
CD patients. In this study we present an association screen
mainly for apoptosis and immunity related genes by mic-
rosatellite markers as investigated in a 3-step approach.
Our initial analyses revealed 9 significantly different allele
distributions of intra- or juxtagenic markers for FLIP,
BCL2A1, BAG1, BPI, erbB3, TP73, TLR9, TNFRSF17 and
CARD15 (see Tab. 2). Yet, after correction by Q-value,
none of those markers remained significant. On the other
hand, a recent study raised the question, whether the cor-
rection for multiple comparisons should be applied at all
in EAS [26]. For example, in these analyses a previously
significantly associated microsatellite (representing the
TNFα gene), which has been used as a positive control
such as CARD15, would have been rejected by the correc-
tion procedure. Therefore, it remains conceivable that the
abovementioned markers represent rather hints for addi-
tional predisposing factors/loci with low effect size.
Table 3: Investigated SNPs in genes as represented by significantly differing microsatellites of the individual genotyping step.
Gene rs# Allele 01/02 Oligonucleotides (sense/antisense) RE TM (°C) Allele: fragment length 
(bp)
FLIP Rs7583529 A/C GGTGATTATTCGGACCCCA/
AACTACAGATCCCGTGTGGAG
TseI 57 01: 155
02: 103/52
Rs2041765 T/C GAACAAGGAGAGAACCTGGAC/
GAGCTGGAAGGCACAGTACA
MboII 56 01: 309
02: 188/121
TNFRSF17 Rs3743591 A/G ATAAGCAGTTTCTGTTTCAGATGT/
CTCTACAAGAATTCCAGAGCA
BceAI 55 01: 223
02: 147/76
Rs11570139 C/T GCCCTGATATTTACACCCTGT/
CAGCCATCTGCAACATGAT
CaiI 54 01: 269
02: 161/108
Rs373496 T/C AGGAACTGAAACTCACAATAGC/
CAGCTCATTATCTGTCTGATGTT
AluI 55 01: 247
02: 100/90/54/3
MHC2TA Rs3087456 G/A * 1 GTGAAATTAATTTCAGAGCTGT/
CTCAGCTTCCCCAAGGAT
BfmI 58 01: 268
02: 231/37
Analyses were performed by using the RFLP method. The table depicts information on the used SNPs as well as RFLP/PCR conditions. * 1 A 5'-tail 
was added to the mismatch (bold letter) sense primer (5'-CATCGCTGATTCGCACAT-3'). PCR was performed with a third oligonucleotide with 
the equal sequence as the tail. RE: restriction enzyme; TM: melting temperature (used for annealing in PCR).Journal of Negative Results in BioMedicine 2005, 4:8 http://www.jnrbm.com/content/4/1/8
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The most promising markers (reflected by a significant p-
value) were included in further analyses regardless of the
correction procedure. Individual genotyping rejected
most markers found to be significantly different in the ini-
tial step of our approach and only three markers remained
significant representing the TNFRSF17,  FLIP,  CARD15
genes (Tab. 2). Obviously, pooled and individual geno-
typing yield somewhat contradictory results. Eight micro-
satellites revealed significantly differences between the
patient and control cohorts after the pooling procedure,
whereas individual genotyping results in the confirmation
of 'only' 2 markers. These conspicuous differences might
be due to several artefacts caused by analyses with pooled
DNA. For example, a typical artefact is the length-depend-
ent amplification of short alleles or the presence of null-
alleles. Additionally, consistency of the analyses by a slab-
gel system might reflect a further hindrance in this subtle
procedure. Nevertheless, individual genotyping elimi-
nates false positive results due to pooling artefacts and, in
case of significant results, enables the thorough analyses
of the marker alleles in detail (see Fig.1). In order to con-
firm the aforementioned positive results further markers
(SNPs, Tab. 3) were genotyped located in the respective
genes in the vicinity of the microsatellites representing
TNFRSF17 and FLIP. Yet, RFLP analyses did not reveal any
association of the selected SNPs and, therefore, the micro-
satellite data were not confirmed. On the other hand,
these SNPs might not represent regions properly that
encompass regulatory elements.
In some instances, the LD of distinct microsatellite alleles
covers long genetic distances, thus further gene variations
might be in linkage with these alleles. Since the signifi-
cantly associated 'TNFRSF17' marker is located at the
IBD8 region with 1MBp distance to the major histocom-
patibility class (MHC) II transactivator (MHCIITA), a pre-
viously reported functional variation of the MHC2TA
gene was analysed (see Tab. 4; [30]). MHC2TA regulates
the expression of human leukocyte antigen (HLA) genes reg-
ulating the adaptive immune system by presenting anti-
gens to CD4+ T cells, thereby re-activating these cells. The
HLA region has been implicated in IBD [32]. In addition
to the localisation of MHC2TA at IBD8 and the associated
marker in the adjacent region, the putative biological rel-
evance of the functional rs3087456 polymorphism for
CD motivated us to genotype this variation. The analyses
did reveal a marginal association in our CD patients when
allele or genotype frequencies were compared between
the combined control and patient cohorts (see Tab. 4). Yet
Genotype frequencies of the microsatellite representing the  TNFRSF17 gene Figure 1
Genotype frequencies of the microsatellite representing the 
TNFRSF17 gene. Only genotypes with a frequency of > 0.01 
are included. Alleles of the respective microsatellite are indi-
cated as numbers in the X-axis according to their length in 
bp. For example: 1–1 (read from the number below the 
numerical series and the first number of the numerical 
series) means homozygous genotype for microsatellite allele 
number one and 1–4 heterozygous genotype for allele 1 and 
4. Genotypes comprising allele 2 are over-represented within 
the control group (47% vs. 29%; pc = 0.0042 with c = 2), 
whereas allele 3 genotypes are more frequent in the patient 
cohort (58% vs. 52% pc = 0.3130; c = 2). Therefore, allele 2 
might imply a protective effect and/or allele 3 a predisposing 
effect on CD. Interestingly, the genotype 2–3 is more preva-
lent in the control group. This result can be interpreted by a 
different effect size of allele 2 (↑) as compared to allele 3, or 
the significant difference of this microsatellite is only due to 
linkage of allele 2 with a protective factor.
Table 4: Allele and genotype frequencies of the functional MHC2TA polymorphism (rs3087456).
Allele frequencies p value OR (CI) Genotype frequencies p value
CD (n = 147) C 0.32 0.05 1.33 (0.90–2.01) CC 0.08 0.54
T 0.68 CT 0.48 0.06
TT 0.44 0.03
controls (n = 463) C 0.26 CC 0.07
T 0.74 CT 0.39
TT 0.54
OR: odds ratio; CI: 95% confidence intervalJournal of Negative Results in BioMedicine 2005, 4:8 http://www.jnrbm.com/content/4/1/8
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there was no evidence for LD between TNFRSF17  and
MHC2TA alleles. In order to validate these data further
patient cohorts comprising more individuals must be
scrutinised. In addition, other genes that might be linked
with the 'TNFRSF17' marker must be analysed (at least 15
RefSeq genes in the region are encompassed by the micro-
satellite marker and MHC2TA).
In conclusion, this study did not reveal overt evidence for
CD predisposition factors in apoptotic (and immune)
pathways. Certainly, our approach depends on the LD
between the investigated microsatellites and putative pre-
disposing or protective alleles, depending on functional
relevance to the disease. Thus, in some instances micros-
atellites might not be entirely representative for the adja-
cent genes. Furthermore, the investigated genes only cover
part of the factors which coordinate programmed cell
death. Yet, future information about haplotype blocks
may facilitate more far-fetched interpretations of our anal-
yses.
Additional material
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